Loading current stock analysis…
Loading current stock analysis…
India
Reported ownership for FY2027-Q2 as of 2026-09-30.
As of 06 Nov 2026, 03:30 pm
For the quarter ended September 30, 2026, Fortis reported a 17.3% year-on-year revenue growth to ₹2,735 crore. However, consolidated net profit declined by 3% to ₹312.4 crore, as lower exceptional gains offset the top-line expansion.
The company outlined expansion initiatives including the acquisition of Suguna Hospital in Bengaluru and a definitive agreement for a new super-specialty facility in New Delhi. Additionally, its diagnostics arm, Agilus, expanded its network to 4,551 touch points.
Auditors noted an ongoing SFIO investigation into alleged improper transactions and a Delhi High Court order appointing a forensic auditor for transactions involving Fortis and RHT Health Trust. The Supreme Court allowed this audit to proceed on September 25, 2026, though the auditor’s conclusion remained unmodified.
As of November 6, 2026, the stock closed at ₹766.9, down from a previous close of ₹819.8. The stock is trading within a significant drawdown, with a current drawdown of -30.1% and a maximum drawdown of -35.1%. Year-to-date returns stand at -14.8%.
As of 06 Nov 2026, 03:30 pm
Recent drawdown or price variability is materially high and may lead to larger short-term outcomes.
Primary driver: Price remains materially below a previous peak
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
The session opened materially above the previous close, indicating a sharp repricing at the open.
The move may reflect new information; subsequent price follow-through is worth monitoring.
Latest complete financial results for Q2 FY27 and comparative quarterly trends.
| Metric | Q2 FY26 | Q1 FY27 | Q2 FY27(Latest) |
|---|---|---|---|
| Revenue From Operations | ₹2,331 crore | ₹2,545 crore | PEAK₹2,735 crore |
| Expenses | ₹1,956 crore | ₹2,210 crore | PEAK₹2,318 crore |
| Profit Before Exceptional Items And Tax | ₹398 crore | ₹349 crore | PEAK₹423 crore |
| Profit Before Tax | ₹422 crore | ₹359 crore | PEAK₹426 crore |
| Profit Loss For Period | PEAK₹329 crore | ₹273 crore | ₹320 crore |
| Tax Expense | ₹96.6 crore | ₹90.4 crore | PEAK₹112 crore |
Fortis Healthcare’s revenue from operations rose 17.3% year on year to ₹2,735 crore in Q2 FY2026-27, while profit before tax increased 1.1% to ₹426 crore. Sequentially, revenue grew 7.5% and profit before tax 18.8%, with expenses rising more slowly than revenue. Profit from continuing operations and EPS, however, remained below the year-earlier quarter.
Operating cash flow was ₹752 crore in Q2. Investing activities used ₹478 crore and financing activities used ₹656 crore; reported free cash flow was ₹274 crore.
Cash and cash equivalents stood at ₹150 crore on 30 September 2026, down from ₹407 crore on 31 March 2026. Bank balances other than cash equivalents were ₹187 crore at quarter-end. Current financial liabilities increased to ₹2,107 crore from ₹1,484 crore at 31 March 2026.
Fortis recorded strong sequential growth in revenue and pre-tax profit, with expenses growing more slowly than revenue. Year-on-year earnings growth was weaker: profit before tax was nearly flat, while profit from continuing operations and EPS declined. Positive quarterly operating cash flow and free cash flow coincided with lower cash and higher current financial liabilities at 30 September 2026.
Disclosed bulk and block transactions involving Fortis Healthcare, shown for the latest 90 days.
Exchange disclosures and regulatory announcements for Fortis Healthcare.
Fortis Healthcare Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
Fortis Healthcare Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL
Fortis Healthcare Limited has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
Fortis Healthcare Limited made available the audio recording of its investors/analysts meeting held on November 6, 2026, to discuss the company’s unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company stated that the recording is available on its website.
On November 5, 2026, Fortis Healthcare Limited’s Board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The filing includes limited review reports and a certificate on compliance with financial covenants. The standalone auditor’s conclusion was unmodified, but it drew attention to the ongoing SFIO investigation concerning alleged improper transactions and to the Delhi High Court’s August 31, 2026 order appointing a forensic auditor to examine transactions involving Fortis and RHT Health Trust; the Supreme Court allowed the audit to proceed on September 25, 2026. The auditor stated that its conclusion was not modified in respect of these matters.
Fortis Healthcare Limited presented Q2 FY27 and H1 FY27 results for the periods ended September 30, 2026. For Q2 FY27, consolidated revenue from operations was INR 2,734.8 crore, net profit before exceptional items and tax was INR 429.3 crore, and net profit attributable to owners from continuing operations was INR 312.4 crore. The presentation also reported the October 2026 acquisition of Suguna Hospital, a 110-bed facility in Rajajinagar, Bengaluru, for approximately INR 277 crore in an all-cash deal, and September 2026 definitive agreements for a 29-year healthcare services arrangement at a planned 400+ bed hospital in Ashok Vihar, New Delhi. The exchange notice transmitting the presentation is routine; the operating results and business developments disclosed are substantive.
Fortis Healthcare Limited announced its unaudited consolidated financial results for the quarter and half-year ended September 30, 2026 (Q2 FY27). Consolidated revenues rose 17.3% to INR 2,735 Cr, while Profit After Tax (PAT) declined 2.5% to INR 320 Cr due to lower exceptional gains compared to the prior year period. The company reported net debt of INR 2,188 Cr with a Net Debt to EBITDA ratio of 0.87x. In operational developments, Fortis acquired Suguna Hospital, a 110-bed facility in Bengaluru, and entered into definitive agreements via subsidiary Fortis Hospotel Limited to provide services for a 400+ bed super-specialty hospital in New Delhi.
Fortis Healthcare Limited filed unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, with a net profit of Rs. 17,697 lacs (half-year) and Rs. 12,991 lacs (quarter). The filing includes a limited review report by statutory auditor B S R & Co. LLP, which highlights ongoing Serious Fraud Investigation Office (SFIO) investigations into alleged improper transactions and non-compliances dating back to pre-2018 periods. Additionally, the Supreme Court has allowed a forensic audit ordered by the Delhi High Court on August 31, 2026, to examine transactions between Fortis and RHT Health Trust, while the Company confirmed its acquisition of the 'Fortis' brand trademarks via court auction in 2024/2025.
Recent market and company developments associated with Fortis Healthcare.
The Sensex and Nifty extended their winning streak to seven consecutive sessions, with the Nifty 50 closing at a nine-month high above 25,000. The rally was primarily driven by heavy buying in banking heavyweight stocks and strong quarterly earnings from Mahindra & Mahindra. Conversely, select midcap stocks underperformed due to disappointing growth or cautious outlooks, causing the Nifty Midcap Index to slip despite the broader market gains.
The market is reacting to Q2 earnings from companies that reported after hours on Thursday, including LIC, Bharti Airtel, Titan, ONGC, and Fortis Healthcare. Today's trading session features results from Hindalco, Voltas, Jubilant Foodworks, and Honasa Consumer, alongside other broader market names. These updates are expected to influence investor sentiment as the final trading day of the week concludes.
Fortis Healthcare reported a 3% year-on-year decline in consolidated net profit to ₹312.4 crore for Q2 FY27, as lower exceptional gains offset a 17.3% revenue growth to ₹2,735 crore. The company also announced expansion initiatives, including the acquisition of Suguna Hospital in Bengaluru and a definitive agreement for a new super-specialty facility in New Delhi, while its diagnostics arm Agilus expanded its network to 4,551 touch points.
Indian equity markets are set for a cautious opening on Thursday as traders assess the global monetary policy and rising crude oil prices.
Buzzing stocks feature TVS Motor demerger, Fortis, Dr Reddy’s updates, leadership shifts at Bajaj Electricals, plus new orders, expansions, and regulatory news.
Jay Thakkar has recommended three stocks to buy today. He suggests buying Fortis Healthcare, LTM and BSE stock futures.
The 110-bedded hospital in Rajajinagar reported revenue of around ₹50 crore in FY26 and has the potential to expand to 150 beds.
Fortis Healthcare Ltd completed the all-cash acquisition of Suguna Hospital in Bengaluru for ₹277 crore via a slump sale structured through its subsidiary International Hospital Ltd. The deal adds a 110-bed facility to Fortis's portfolio, bringing its total operational beds in the city to approximately 1,000.
Comprehensive Section Breakdown for Fortis Healthcare
Strategic Vision: Integrated healthcare delivery services provider in India.
• Network of hospitals and diagnostic services
• Integrated healthcare delivery model
Revenue from operations increased from ₹2,545 crore in Q1 FY2026-27 to ₹2,735 crore in Q2; it was ₹2,331 crore in Q2 FY2025-26. Revenue has risen in each quarter since Q3 FY2025-26, when it dipped to ₹2,265 crore.
Expenses rose 4.9% quarter on quarter to ₹2,318 crore, below the 7.5% growth in revenue. Profit before exceptional items and tax increased 21.2% sequentially to ₹423 crore. Profit before tax rose 18.8% to ₹426 crore from Q1 FY2026-27 and 1.1% from ₹422 crore in Q2 FY2025-26.
Q2 expenses included ₹601 crore of purchases of stock in trade, ₹409 crore of employee benefit expense and ₹128 crore of depreciation and amortisation. Finance costs declined 2.7% quarter on quarter to ₹78 crore from ₹80 crore, but were 4.6% higher than in Q2 FY2025-26.
Exceptional items were a charge of ₹2.98 crore in Q2, compared with a charge of ₹9.53 crore in Q1 FY2026-27. Tax expense increased 23.7% sequentially to ₹112 crore, comprising current tax of ₹102 crore and deferred tax of ₹9.5 crore.
Profit from continuing operations rose 17.1% quarter on quarter to ₹314 crore, but declined 3.3% from ₹325 crore in Q2 FY2025-26. Total profit for the period was ₹320 crore, including ₹312 crore attributable to owners of the parent and ₹8.1 crore to non-controlling interests. EPS was ₹4.14, up from ₹3.53 in Q1 FY2026-27 and down from ₹4.26 a year earlier.
Total assets were ₹16,415 crore at 30 September 2026, compared with ₹15,966 crore at 31 March 2026. Property, plant and equipment stood at ₹7,020 crore, up from ₹5,348 crore at March-end, while capital work in progress was ₹495 crore. Goodwill was ₹4,737 crore.
Trade receivables increased to ₹1,323 crore from ₹1,044 crore at 31 March 2026. Equity attributable to owners of the parent rose to ₹10,478 crore from ₹9,896 crore. Non-current borrowings were ₹2,502 crore, compared with ₹2,401 crore at March-end.
Category: B2B Services
Agilus Diagnostics provides diagnostic services as a significant part of Fortis's offering.
Key Products & Services: Agilus Diagnostics
Category: Healthcare Services
Fortis operates a network of hospitals across India, offering a range of medical facilities and specialized care.
Key Products & Services: Fortis CDOC • Fortis Escorts Heart Institute • Fortis Escorts Hospital • Fortis Hospital
Core Thesis: The company aims to deliver integrated healthcare by combining medical expertise with compassionate service.
• Clinical Excellence: Fortis is recognized for its clinical excellence in providing healthcare services. • Patient Care: The company focuses on delivering compassionate service alongside medical expertise. • Integrated Delivery: Fortis provides integrated healthcare through its network of hospitals, specialty facilities, and diagnostics.